Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...
Free to browse, no account needed Follow the companies behind these drugs with free AI briefings, catalyst countdowns and dilution alerts.
Start 7-day free trial → Log in

Dianhydrogalactitol · VAL-083, NSC-132313

Small molecule · Cytotoxic, directed at DNA · developed by Kintara Therapeutics

Phase 2/3 Most advanced trial
1 Registered trials

What is Dianhydrogalactitol?

Dianhydrogalactitol (VAL-083) is a bifunctional hexitol derivative that alkylates and cross-links DNA via an epoxide group, disrupting DNA function and causing cell cycle arrest. It is studied in glioblastoma.

Summary written with AI from the sources listed at the end of this page.

At a glance

Also known as
VAL-083, NSC-132313
Drug type
Small molecule
Targets
DNA
Mechanism
Cytotoxic, directed at DNA
Pathways
DNA cross-linking, cell cycle arrest
Therapy area
Oncology
Developer
Kintara Therapeutics, Inc.
In trials of
BHVN
FDA status
Investigational, not approved in the US. Most advanced trial: Phase 2/3
UNII
4S465RYF7M

🧪 Clinical trials

TrialPhaseConditionStatusSponsor
NCT03970447 Phase 2/3 Glioblastoma Recruiting BHVN

Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.

Conditions studied

Glioblastoma

Sources

Updated Oct 3, 2026.

Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z

This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.